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Since its identiﬁcation in 1981, several pub-
lications have described the condition cur-
rently known as toxic oil syndrome (TOS)
and the outbreak of TOS that affected some
20,000 people (and killed over 300 in the
ﬁrst 20 months) in Madrid and in the north-
west provinces of Spain. The novelty of the
condition (which did not correspond to any
known nosologic category), the complexity
of its etiology and pathogenesis, and the
uncertainties of its evolution led the Spanish
government to request the collaboration of
the World Health Organization (WHO)
Regional Ofﬁce for Europe, which has now
lasted for almost 20 years. 
In 1987, the WHO Regional Ofﬁce for
Europe and the Spanish government formal-
ized the collaboration and laid the founda-
tion for a jointly supervised, intensive
international research program. In 1996, the
Spanish government created a center for
investigating the disease at the Institute of
Health Carlos III in Madrid (Centro de
Investigación para el Síndrome del Aceite
Tóxico, or CISAT). The collaboration is
being carried out under the guidance of the
joint WHO/CISAT Scientific Committee
for the Toxic Oil Syndrome. The joint com-
mittee had held 29 meetings by mid-2001.
Case definition and identification of
TOS patients have not been major problems.
Four major and a number of minor criteria
for case deﬁnition were established early after
the outbreak of the condition (1), and their
application has met with very few difﬁculties.
The same criteria were applied in the retro-
spective creation in the mid-1980s of an
exhaustive registry of affected people [the
“census,” which is kept at CISAT and was
retrospectively and carefully reviewed in the
late 1980s; see World Health Organization
(2)]. The census has been the basis for follow-
up studies of the TOS cohort.
In the early phases of the outbreak of
TOS, because the clinical picture was similar
to that of acute infectious pneumonitis, the
possibility of an infectious etiology, such as
Legionella and/or Mycoplasma, was seriously
considered. Many patients were treated with
erythromycin and/or tetracycline antibiotics,
with no beneﬁt. At the same time, rumors or
reports surfaced regarding an association of
the illness with a particular vector or vehicle,
frequently with an unclear notion of the pre-
cise nature of the causal agent. Onions, straw-
berries, asparagus, and chicken were variously
implicated by different observers. Reports that
the disease was being carried by cats, dogs,
and birds led to the slaughter of many pets.
After what most considered the defini-
tive identiﬁcation of oil as the vehicle of the
TOS agent, on 10 June 1981, only a few
alternative theories maintained any support.
The most prominent and persistent of these
was that the epidemic was the result of
contamination of tomatoes and perhaps
other produce grown in Andalusia with
organophosphates, particularly isofenphos
and fenamiphos. Although the theory gener-
ated much media publicity, it was to be dis-
carded because of the clear-cut differences of
the syndrome from classical organophos-
phate toxity, the lack of any report on the
presence of organophosphorus compounds
in case-related oils (2), and the absence of
any other supporting evidence. 
In 1987, the epidemiologic evidence was
strong that TOS was causally associated with
Address correspondence to B. Terracini, Centro per
la Prevenzione Oncologica, Dipartimento di Scienze
Biomediche e Oncologia Umana, Università di
Torino, Via Santena 7, 10126 Torino, Italy.
Telephone: 39 011 670-6526. Fax: 39 011 670-6692.
E-mail terracini@etabeta.it
The WHO/CISAT Scientiﬁc Committee for the
Toxic Oil Syndrome includes E. Gelpí (Chairman),
M. Posada de la Paz (General Coordinator), B.
Terracini (Rapporteur for the present paper), I.
Abaitua, A. Gómez de la Cámara, E.M. Kilbourne,
C. Lahoz, B. Nemery, R.M. Philen, L. Soldevilla,
and S. Tarkowski. 
We are grateful to R. Goulding for his chairman-
ship of the committee until 1992. A vital and
thoughtful input to the activity of the committee
was given by the late N. Aldridge. 
We gratefully acknowledge the support and secre-
tarial and technical help of the World Health
Organization Regional Office for Europe and of
the Toxic Oil Syndrome Research Center (CISAT)
of the Institute of Health Carlos III.
Received 13 July 2001; accepted 4 December
2001.
Reviews
In 1981, in Spain, the ingestion of an oil fraudulently sold as olive oil caused an outbreak of a
previously unrecorded condition, later known as toxic oil syndrome (TOS), clinically character-
ized by intense incapacitating myalgias, marked peripheral eosinophilia, and pulmonary infil-
trates. Of the 20,000 persons affected, approximately 300 died shortly after the onset of the
disease and a larger number developed chronic disease. For more than 15 years, a scientiﬁc com-
mittee supported by the World Health Organization’s Regional Office for Europe and by the
Institute of Health Carlos III in Madrid has guided investigation intended to identify the causal
agent(s), to assess toxicity and mode of action, to establish the pathogenesis of the disease, and to
detect late consequences. This report summarizes advances in research on this front. No late mor-
tality excess has been detected. Among survivors, the prevalence of some chronic conditions (e.g.,
sclerodermia, neurologic changes) is high. Attempts to reproduce the condition in laboratory ani-
mals have been unsuccessful, and no condition similar to TOS has been reported in the scientiﬁc
literature. Laboratory ﬁndings suggest an autoimmune mechanism for TOS, such as high levels of
seric soluble interleukin-2 receptor. Epidemiologic studies integrated with chemical analyses of
case-related oils have shown that the disease is strongly associated with the consumption of oils
containing fatty acid esters of 3-(N-phenylamino)-1,2-propanediol (PAP). These chemicals have
also been found in oils synthesized under conditions simulating those hypothesized to have
occurred when the toxic oil was produced in 1981. Whether PAP esters are simply markers of
toxicity of oils or have the capability to induce the disease remains to be elucidated. Key words:
autoimmunity, foodborne intoxication, oleyl anilide, 3-phenylamino-1,2-propanediol esters, rape-
seed oil, toxic oil syndrome. Environ Health Perspect 110:457–464 (2002).      [Online 29 March
2002]  http://ehpnet1.niehs.nih.gov/docs/2002/110p457-464gelpi/abstract.htmlthe ingestion of a food-grade rapeseed oil
containing aniline derivatives and sold for
human consumption by itinerant street ven-
dors (2). Such evidence satisfied some of
Bradford Hill’s (3) traditional causality crite-
ria: the strength of the association, the tem-
poral sequence, and the evidence for
dose–response relationship. The latter had
been shown in a study [so-called “toxi-epi”
study; see Kilbourne et al. (4)] that com-
pared the concentration of fatty acid anilides
[particularly oleylanilide (OA) given that
oleic acid is the most abundant fatty acid in
edible rapeseed oil] between case-related and
control oils. Findings of the toxi-epi study
(4) were subsequently reproduced on a dif-
ferent subset of oils (5), thus satisfying
Bradford Hill’s criterion of consistency of
results among independent studies. Posada
de la Paz et al. (6) also found that rapeseed
oils originating from France had been
imported to Spain (allegedly for industrial
use) after denaturation with 2% aniline, ille-
gally refined to remove aniline, and finally
mixed with other edible oils at a clear proﬁt
for the people involved in this operation.
Reports on the etiology, epidemiology,
clinics, immunology, and pathology of TOS
collected up to 1992 have been published by
the WHO (2). The condition reﬂects a multi-
systemic disease of unknown pathogenesis,
initiated by a non-necrotizing endothelial
injury, with a likely autoimmune component
in its inception and/or evolution. Among
TOS survivors, chronic conditions affecting
the skin, lungs, neurologic system, muscles,
liver, and other organs have been reported.
The present report reviews estimates of the
prevalence of these changes. No excesses of
complicating conditions (such as cancer) had
been detected during the ﬁrst decade of the
disease (2). Rapeseed oils refined with
processes thought to mimic those leading to
the production of the toxic agent in 1981 had
failed to produce relevant toxic effects in labo-
ratory animals (2). As substantiated by a sys-
tematic literature search (7), no animal model
for TOS (i.e., either the spontaneous occur-
rence in laboratory or domestic animals of a
complex condition comparable with TOS or
its experimental induction by any treatment)
can be found in the scientiﬁc literature. The
toxic agent(s) in the rapeseed toxic oil had not
been identiﬁed: aniline itself could be ruled
out, given that its toxic effects are totally
unrelated to changes typical of TOS.
Thus, in the early 1990s, further investi-
gation focused on the natural history of
TOS, the composition of case-related oils
and their effects on laboratory animals, and
the simulation of the refining process (8).
The present report describes advances along
these lines made during the last decade. The
scientific strategy that has been developed
may be a model for investigating foodborne
chemical disasters caused by previously
unknown hazards and producing novel
pathologic conditions.
Mortality of the TOS Cohort in
the Second Decade after the
Disaster
Early and late death rates among censused
TOS victims have been compared with both
the Spanish population and the population
living in the 14 provinces hit by the out-
break (9,10). Since the late 1980s, interven-
ing deaths are identified at yearly intervals
through contact (via mail or telephone) with
the patient or the patient’s family (9). A
number of quality controls have provided
confidence on the exhaustiveness of the
identiﬁcation of deaths (10). Certiﬁed causes
of death have been collected from other
sources (registrars of the town where death
occurred, files of the Spanish National
Institute of Statistics).
During the first 20 months of the out-
break, 262 excess deaths occurred (75 men
and 187 women) among individuals who
had been affected by TOS, a ﬁgure similar to
early estimates (11). A higher mortality rate
among women, particularly young women,
has been recognized since 1981 (11), which
may reflect a higher consumption of toxic
oils and/or a greater sensitivity of women to
the toxic compound.
The excess deaths observed through the
end of 1982 were followed by a persisting
deﬁcit. A total of 832 men and 858 women
died between 1983 and 1997: during the tri-
ennia 1983–1985, 1986–1988, 1989–1991,
1992–1994, and 1995–1997, standardized
mortality ratios for all deaths were, respec-
tively, 0.68, 0.73, 0.64, 0.87, and 0.82 in
men and 0.52, 0.78, 0.75, 0.91, and 0.81 in
women (10,12). Reasons for these low esti-
mates have not been clariﬁed (10).
The only sex/age group in which an
excess of deaths persisted after 1983 com-
prised women under 40 years old, in which
observed-to-expected ratios were 38/16.4
during 1983–1988 and 24/15.6 during
1989–1994, both statistically significant at
the p < 0.05 level. The ratio decreased to
7/8.43 during 1995–1997 (13). In 31 of 62
women who died before 1994, the persis-
tence over the years of a severe condition
typical of the intermediate or early chronic
phases of the condition (e.g., cachexia, lung
hypertension) could be traced in the clinical
records (13).
Prevalence of Chronic
Conditions in the 1990s
A systematic and consistent pattern of late
features of TOS has been identified from
three large studies (14–16). All provide
point prevalence estimates (persons showing
signs among persons affected by TOS) sev-
eral years after the outbreak. Findings are
consistent among the three studies: Neuro-
muscular and skin changes are common, as
well as subjective complaints. Prevalence of
both contractures and obvious motor neu-
ropathy was around 10%; cramps and pares-
thesias were reported, respectively, by
70–80% and 60–70% patients, whereas
patients complaining from musculoskeletal
pain ranged between 30% and 80%. Clear
sclerodermia was present in 9–13% patients.
Pulmonary hypertension and chronic liver
impairment were diagnosed in 1–3% and
1–7% patients, respectively. Other condi-
tions noticed in long-term TOS survivors
were hyperlipidemia (total cholesterol > 240
mg/dL) in 44%, obesity (body mass index >
30) in 40%, hypothyroidism in 7%, and dia-
betes mellitus in 7–9%. The latter ﬁnding is
of interest because another study estimated a
2-fold risk for diabetes among TOS patients
and, in addition, reported vascular pancreatic
lesions in some dying patients (17).
Although these prevalence estimates are
somewhat imprecise because of selection bias
(insufﬁcient participation in otherwise well-
designed studies and lack of an adequate
comparison group), consistency among dif-
ferent studies is remarkable.
TOS patients have frequently reported
peripheral neurologic impairment that could
not be detected by the traditional neurologic
examination. A recent investigation using
quantitative neurologic tests has shown a
good correlation between subjective com-
plaints and objective ﬁndings. In women of
all ages and in men more than 55 years old,
distal strength has the highest predictive
value for the identification of objective
ﬁndings (18).
An overall poor self-assessment of health
status has been estimated in studies using tools
such as the Health Assessment Questionnaire
(19) and the Nottingham Health Profile
Questionnaire (20). Compared with previous
studies on samples of the Spanish general pop-
ulation, impairment scores of TOS patients
obtained with the latter questionnaire were
three times higher (21).
In an ongoing activity related to the
process held in the Spanish court in 1997,
TOS-induced damage over 15 years is being
medically and legally evaluated in 17,000
individuals. Those recognized as suffering
from “great incapacity” (who require the
help of others to carry out daily life activi-
ties) and “absolute permanent incapacity”
(inability to carry out any type of work)
number, respectively, 101 and 209 (22).
Those recognized by the Spanish National
Institute of Social Security to suffer from
“total permanent disability” (corresponding
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ties) number 3,477, two thirds of whom are
women, with a median age of 37 years (23).
Searching for the Causal
Agent: Characterizing
Case-Related Oils
The two toxi-epi studies (4,5) could be car-
ried out thanks to the creation of a perma-
nent collection of oils and their containers
that consumers returned in exchange for safe
olive oil provided by the Spanish govern-
ment in June 1981. Many oils were returned
on the basis of fear and were not related to
the occurrence of cases of TOS. Thus, the
oleoteca (oil repository) is a systematically
compiled and organized collection of oils rel-
evant or possibly relevant to further scientiﬁc
investigation (24). 
Additional evidence indicated that one
particular set of oils was the point source of
the epidemic (24). It had been produced at
the Industria Trianera de Hidrogenación
(ITH) reﬁnery in Seville and distributed by 
a firm in Madrid whose acronym was
RAELCA.
During the 1990s, stored case-related
oils and other suspected oils have been
analyzed with new, more sophisticated
methods, particularly with liquid chro-
matography combined with atmospheric
pressure ionization tandem mass spectrom-
etry (25). A new group of chemicals associ-
ated with the risk of disease were so
identiﬁed (26): the fatty acid esters of 3-(N-
phenylamino)-1,2-propanediol (PAP)—its
1-oleyl-ester (O PAP) and 1,2-di-oleyl ester
(OO PAP) (Figure 1). Indeed, their pres-
ence in case-related oils was reported as
early as 1984 (27). In reanalyses of the oils
used in the two toxi-epi case–control stud-
ies, OO PAP turned out to be a more spe-
cific marker of case relatedness than did
OA. In both toxi-epi studies, among oils
returned from nonaffected families, the
proportion of those that were devoid of
OO PAP was higher than the proportion of
those that were devoid of OA: respectively,
59/64 and 41/64 in the first study and
70/70 and 54/70 in the second study.
Therefore, in statistical terms, the associa-
tion was stronger for OO PAP than for OA
(28). OO PAP was also found in a sample
of oil retrieved from the ITH refinery, but
not in an oil derived from aniline-dena-
tured rapeseed oil illegally produced at
other refineries nor in unrefined aniline-
denatured samples of rapeseed oil sent to
ITH (26). Something unique must have
occurred to a subset of aniline-denatured
oils at ITH that both rendered them toxic
and led to the appearance of OO PAP;
these two consequences are not necessarily
interrelated.
Finding Out the Dynamics of
the “Accident”
During refining, the degumming and neu-
tralization steps remove phospholipids and
free fatty acids, bleaching takes off the color,
and odoriferous compounds are eliminated
through distillation at high temperature
under vacuum, using steam as stripping gas
(27). Reconstructing what went wrong in
one or more of these phases of the process
that eventually led to the production of a
highly toxic oil in 1981 would be of much
benefit for both the identification of the
causal agent of TOS and the prevention of
other similar “accidents.”
In fact, not until 1993 was it possible to
trace (with difﬁculty) and interview workers
in ITH and other refineries (Danesa-Bau)
known to have been involved in the circuits
of illegal oils in Spain in the early 1980s.
Oils from the latter contained no PAP esters
and less OA than did case-related oils (26).
This ﬁnally led to ﬁrmer hypotheses on how
the refining stages could have been imple-
mented when the toxic oil was produced.
Such hypotheses were then tested
through the experimental processing of ad
hoc denatured rapeseed oils, and a number
of possibly toxic oils have been produced in
the laboratory. These oils have been assayed
for toxicity in laboratory animals, with
essentially negative results (see below). They
have also been chemically analyzed in the
laboratory, with more interesting results. It is
reasonable to believe that the processes more
likely to reproduce what happened at the
time of the accident are those leading to the
production of oils containing aniline deriva-
tives at concentrations as high or higher than
those estimated in the sample of oil originat-
ing from ITH oil (OA ≥ 1,900 ppm; OO
PAP ≥ 150 ppm).
In 1995, PAP esters were found in two
samples of rapeseed oil after, but not before,
bringing them to a temperature of 300°C for
4 hr (26). Subsequent experiments at the
Instituto de la Grasa in Seville (29,30)
expanded these findings: Heating at 300°C
but not at 250°C led to the formation of
PAP esters. However, PAP esters formed at
300°C were lost during processing at that
temperature. The level of PAP esters main-
tained during the operation time at 300°C
was higher in denatured samples stored for 3
Reviews • Toxic oil syndrome: review of scientific knowledge
Environmental Health Perspectives • VOLUME 110 | NUMBER 5 | May 2002 459
Figure 1. Structural formulas of derivatives of (A) PAP and its esters (B) O PAP and (C) OO PAP. 
H
C HH O
C HH O
C H
HH
N
O
C H
N
O C
H
COH
H
H
H
C
H
HO
HCOC
HCOC
O
HC N
HH
A
B
Cweeks before refining than in denatured
samples stored for only 1 week. Over the
years, it had become obvious that anilides
form spontaneously from the aniline origi-
nally added to denature the oil, when in
contact with oil constituent fatty acids, with
no role of any step of the refining process;
and that these preformed anilides decrease
very little with distillation time upon reﬁn-
ing (29). Thus, in addition to the identiﬁca-
tion of new, more specific markers of
toxicity (PAP esters), new perspectives were
opened by experiments using different com-
binations of temperature, speed of attaining
a high temperature, and pressure in the
deodorization step (30). Transferring find-
ings from lab-scale experiments to the indus-
trial setting leaves a narrow margin for these
variables to generate PAP esters. Therefore,
the chemical events leading to the formation
of toxic compounds must have occurred
only under exceptional and accidental cir-
cumstances. This may explain why toxicity
seems to be linked only to one batch of oil
produced in one reﬁnery.
The Pathogenesis of TOS
A basis for the disease. During the 1980s, the
vascular and histologic changes typical of
TOS clearly showed an inflammatory reac-
tion within areas of fibrosis. Because of the
chemical structure of the fatty acid anilides,
this could be mediated by an early peroxida-
tive free-radical mechanism involving these
compounds (2). Although at this stage this
hypothesis cannot be discarded, more recent
studies have focused on the immunopatho-
logic mechanism of the disease.
In 1990, a comparison was carried out
(31) on sera collected from TOS patients in
the early 1980s and sera retrieved a few
years later from healthy blood bank donors
in the United States. Levels of eosinophil
granule major basic protein (MBP), which
is one of the mediators of eosinophil toxic-
ity, were more than two standard deviations
above those of the controls in 45%, 32%,
and 23% of sera collected from patients in,
respectively the acute (n = 159), subacute
(n = 100), and chronic phases (n = 64) of
TOS. In TOS patients dying in the acute
phase, MBP was identified in 6 of 27 lung
specimens, which suggests a degranulation of
eosinophils in the target organs with subse-
quent damage (31).
Closely related to this finding was the
demonstration of interleukin-5 (IL-5)
mRNA in paraffin-embedded lung tissue.
This interleukin is directly related with
eosinophil increase (32). An investigation on
cytokines (33) analyzed 26 lungs from TOS
patients who died during 1981–1982 with
signs typical of TOS, which were compared
with 15 patients with no immunologic
diseases who died in 1992–1993, with a sim-
ilar age and sex distribution. Lung specimens
could be traced for speciﬁc mRNA for IL-4
and IL-5 from the TH2 subset of T lympho-
cytes and for IL-2 and γ-interferon (γ-IFN)
from the TH1 subset. The study also ana-
lyzed mRNA for IL-1α, CD25, CD23, and
granulocyte macrophage colony–stimulating
factor. The study found TH2 cytokines
(IL-4 and IL-5) in a significantly higher
proportion of cases than controls (18/26 vs.
3/15, p = 0.003), and also TH1 cytokines
(IL-2 and γ-IFN) in a higher proportion of
cases than controls (8/26 vs. 0/15, p =
0.006). The increment of TH2 versus TH1
in TOS patients was statistically significant
at p = 0.03 (33).
Parallel observations, not reaching statis-
tical significance, were the increases in the
mean immunoglobulin E (IgE) levels (277
vs. 113 UI/mL) and in the mean values of
sCD23 (soluble low-afﬁnity receptor for IgE;
157.1 vs. 50.1 UI/mL) (34). The increased
expression of IL-5 and IL-4 could explain the
early eosinophilia and the elevated IgE levels,
respectively. These ﬁndings point to a T-cell
activation, and this is reinforced by the
demonstration of high levels of soluble inter-
leukin-2 receptor (sIL-2R) in the sera of 98
TOS patients in the acute phase compared
with 28 controls attending the same hospi-
tals for other conditions (1,810 vs. 892
U/mL; p < 0.0001) (34).
It has been demonstrated experimentally
that one of the accepted markers of oil toxic-
ity, lynolenylanilide, induced apoptosis in
human lymphocytes in a concentration- and
time-dependent manner. In parallel experi-
ments, neither aniline nor some PAP deriva-
tives produced the same effect (35).
In conclusion, the fact that sIL-2R corre-
lates with blood eosinophilia (36) strength-
ens the hypothesis of an immunopathologic
mechanism of the disease. The possible cas-
cade of events in TOS patients is as follows:
T-cell activation, IL-4 and IL-5 release,
eosinophilia, deposition of MBP in tissues,
and organ impairment.
The role of genetic susceptibility factors.
Previous studies have investigated the role of
major histocompatibility complex (MHC).
MHC antigens such as DR3, DR4, and
DQ8 were more frequent among TOS
patients than in a number of control samples
of Spanish people (37). Nevertheless, the
representativeness of the latter is debatable.
Recently, the role of human leukocyte
antigen (HLA) class II antigens was investi-
gated in well-designed case–control studies
(38). One study (38) included 117 chronic
TOS patients, 71 nonaffected family mem-
bers, and 77 unrelated controls. In addition,
the study compared HLA class II antigens
between 34 deceased TOS patients and 13
controls (TOS patients dying from causes
unrelated to TOS). The study found no sta-
tistically signiﬁcant association between the
disease and any HLA antigen, including
those described above: DR3, DR4, and
DQ8. However, an increase in the pheno-
typic frequency of DR2 antigen was found
in 73.5% patients dying from TOS. This
was signiﬁcantly different from the propor-
tion of 38.4% among people dying from
causes other than TOS. The corresponding
proportion was even lower (25–30%) in
three groups of people who were not known
to be dying from any condition: patients
with TOS, nonaffected family members, and
unrelated controls (p < 0.001 for the three
comparisons) (38). Arnaiz-Villena et al. (39)
reported a major DR2 increase in patients
who ﬁrst presented with atypical pneumonia
(only in half of the patients with chronic dis-
ease). This suggested that DR2 could be a
possible protective antigen for the evolution to
the chronic stage (39). The studies of Cárdaba
et al. (38) did not support the later hypothesis
but rather point to the fact that DR2 is an
aggravating factor associated with the severity
of the disease. Underrepresentation in chronic
patients may simply reﬂect the fact that DR2
patients were prone to die from the disease.
Similar to other conditions caused by
toxic chemicals, a role played by the indi-
vidual’s ability to biotransform and elimi-
nate the toxic agent(s) is plausible, regarding
susceptibility both to the onset of the dis-
ease and to its evolution. A recent study
(40) found the NAT2 mutation in both
alleles (corresponding to the phenotype
“slow-acetylators”) in 66 of 70 cases versus
59 of 70 unrelated controls living in the
same area [crude odds ratio (OR), 3.3; 95%
conﬁdence interval (CI), 0.9–12.1; OR esti-
mated under conditional logistic regression,
adjusted for a number of potential con-
founders, 7.0; 95% CI, 1.4–33.2]. Other
investigated metabolic genes were not asso-
ciated to any risk (40).
TOS and eosinophilia–myalgia syn-
drome (EMS). The investigation of TOS
was a key factor in the early recognition and
study of eosinophilia-myalgia syndrome
(EMS) in the United States in 1989.
Another new illness affecting some 1,500
patients, EMS was eventually traced to
ingestion of L-tryptophan produced by the
Showa Denko Company of Japan (41,42).
The clinical features of EMS (43,44) have
much in common with TOS, although the
clinical onset of EMS was usually less dra-
matic, and fewer EMS patients exhibited
serious pulmonary findings. Like TOS,
EMS was more frequent among women,
but it was not limited to a single geographic
area in the United States. Chemical investi-
gations have postulated similarities between
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patients (45,46).
Testing Oils in Laboratory
Animals
Since the early 1990s, the WHO/CISAT sci-
entific committee implemented the rule
that—in addition to suspected chemicals—
only oils of proven case relatedness and oils
refined in attempts to reproduce the “acci-
dent” (heretofore indicated as refined or
reconstituted oils) were to be tested for toxi-
city in projects supported by the committee.
Moreover, testing was done in laboratories
that were blinded with respect to the origin
of the oil.
As yet, six case-related oils, 18 refined
oils, and nine deﬁned chemicals (PAP esters
and fatty acid anilides) have been tested in
short-term experiments, mainly by the oral
route, in more than 3,000 laboratory ani-
mals (Tables 1 and 2) in 15 different labora-
tories. The human and financial resources
implied in this undertaking can be inferred
from these tables. For the most part, these
were short-term experiments, carried out
either in the acute mode (one single maxi-
mum tolerated dose, observation period of 5
days), intermediate mode (7 days at variable
doses, observation period of additional 7
days), or subacute mode (longer treatment
with up to 14 days of observation). In con-
structing Tables 1 and 2, we defined an
experiment as the simultaneous treatment of
a number of animals of the same species and
strain, by the same route, with the same
material, at one or more dose levels and/or
with the same or different schedules.
In principle, in interpreting these data,
which essentially result from a screening
process, progressive categories of biologic
signiﬁcance of the results of each experiment
could be as follows: a) no difference from
control animals, b) some effect, c) internal
consistency within the experiment (i.e.,
dose–response); and d) consistency with
results of other experiments. A detailed pre-
sentation of the results is not the purpose of
the present review. Nevertheless, despite the
dimensions of the screening process, results
so far have been meager. Two promising
findings, in two separate subacute experi-
ments, are the induction of eosinophilia in
Balb/c mice and the induction of an
increased IgE in DBA/2 mice with a reﬁned
oil containing 1,366 ppm OA and 1,065
ppm OO PAP (47). Although these experi-
ments were not designed to detect dose–
response effects, if any, this oil induced more
eosinophilia and higher IgE levels than did
an oil containing only 412 ppm. Similar
findings have been reported in both Balb/c
and DBA/s strains using the reﬁned oil con-
taining 5,681 ppm OA and 412 ppm
OO PAP (47). Interestingly, in these investi-
gations, eosinophilia was measured through
ﬂow cytometry, whereas manual (less sensi-
tive and less reliable) methods were used in
other experiments (47). 
By the oral route, neither PAP nor its
monoester was toxic to Lewis and LAC rats
or to MF1 mice. Nevertheless, 14 intraperi-
toneal daily doses of 150–350 mg PAP per
kilogram of body weight induced mesenteric
and pulmonary thromboembolism in rats.
Intravenous administration showed that the
compound was not directly vasotoxic (48).
None of the other experiments with individ-
ual compounds showed any effect.
Metabolic Studies
In general, studies along these lines are difﬁ-
cult to interpret. For the most part they rep-
resent a collection of interesting but loosely
knit observations, in need of a unifying
theory to bring them all together into the
explanation of the etiopathogenesis of TOS.
Animal metabolism. Most of the work
carried out in this area dates from 1983–1985.
A few reports exist in the literature after this
period, but these are scarce and do not pre-
sent clear-cut conclusions. Of the half dozen
publications that appeared after the WHO
publication in 1992 (2), the following obser-
vations should be considered.
Studies on rat liver metabolism (49,50)
show that N-phenyllinoleamide produces
free aniline and linoleic acid, suggesting a
hepatic amidase activity. Lack of this enzy-
matic activity in humans could be related to
their susceptibility to TOS. Other work on
toxicity responses in male and female rats
examined the effect of anilides and their heat-
generated compounds on various physiologic
parameters (51,52). Several enzyme activities
have been found to be decreased at various
time points (53), but other parameters varied
widely, which is difﬁcult to rationalize into a
common toxic mechanism. The problem
with some of these studies is that metabolic
effects have been also observed for non-case-
related oils (54).
We know little about PAP ester absorp-
tion, distribution, and metabolism. In mice
administered PAP intraperitoneally, oxidized
chemical species derived from aldehyde
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Table 1. Summary of experiments carried out in animals treated with oils.
Total no. of  Total no. Median no.
Animal, strain Oil typea experimentsb of animals of days Anilidesc OO PAPd
Mice
A/J Case oils 4 19 5 11.8 662.5
Reconstituted oils 55 266 5 21.9 42.5
Balb/c Reconstituted oils 49 257 5 34.2 12.5
C57BL/6 Reconstituted oils 44 217 5 26.8 4.6
CBA Case oils 1 10 42 323.4 1302.0
DBA/2 Case oils 4 19 5 11.8 662.5
Reconstituted oils 57 296 5 22.8 42.5
MRL/lpr Case oils 12 338 7 17.4 346.5
Reconstituted oils 24 676 7 161.8 1044.0
Subtotal 246 1,802
Rats
Brown Norway Case oils 1 5 90 277.2 1116.0
Lewis Case oils 3 18 14 13.5 142.3
Sprague-Dawley Case oils 4 78 7 6.8 134.8
Reconstituted oils 8 156 7 61.0 1033.5
Subtotal 16 257
Guinea Pigs
GOHI Case oils 4 78 7 6.8 134.8
Reconstituted oils 8 156 7 66.9 1034.0
NZ Case oils 2 16 28 32.4 341.6
Not speciﬁed Case oils 1 3 21 168.0 5250.0
Subtotal 15 253
Chicks
Not speciﬁed Case oils 1 5 21 22.4 700.0
Dogs
Beagles Case oils 5 11 5 13.5 525.0
Minipigs
Not speciﬁed Reconstituted oils 2 4 7 181.7 7213.5
Monkeys 
Maccaca fascicularis Case oils 3 18 21 21.0 221.0
Subtotal 11 38
Total 288 2,350
aCase oils are oils returned from families where some members have been affected by TOS. Reconstituted oils are oils
synthesized in the laboratory. bAn experiment corresponds to a study carried out with a speciﬁc sample of oil using a
given strain and following a speciﬁc schedule. cMedian of concentration (mg/kg body weight) of oleylanilides ingested
by gavage among all experiments with this type of oils and this strain. dMedian of concentration (µg/kg body weight) of
the 1,2-di-oleyl-ester of 3-(N-phenylamino)-1,2-propanediol ingested by gavage among all experiments with this type of
oils and this strain.intermediates or from hydroxylation at the
aromatic ring have been identified; the
detection of some of these species suggests
the in vivo formation of quinoneimine PAP
derivatives (55). Closa et al. (56) have
reported on the capacity of PAP fatty acid
esters to be absorbed by the gastrointestinal
tract of experimental rats and metabolized in
a similar manner as phospholipids. The
study showed that the fatty acids present in
the PAP molecule can be hydrolyzed and
that different fatty acids can then be incor-
porated by reesteriﬁcation during the process
of gastrointestinal absorption. After absorp-
tion from the gastrointestinal tract, the vari-
ous PAP species are distributed throughout
rat tissues by binding to different organs and
can further be modified by changes in the
fatty acids present in the molecule. Finally,
the fraction of these products not taken up
by various organs and tissues is catabolized
and excreted in urine. Biotransformation in
the gastrointestinal tract involves resynthesis
of new PAPs with different patterns of con-
stituent fatty acids depending on the vehicle
of administration. These are then distributed
and stored in different organs, particularly in
the liver and in brown adipose tissue. A sim-
ilar effect was also reported on guinea pig
liver microsomes, where changes could be
attributable to the free fatty acid contents of
ingested oil (57). Intestinal hydrolysis of
ingested PAP diesters to monoesters and free
PAP has also been reported in Wistar rats
(58). The experiments of Closa et al. (56)
also showed that some PAP esters inhibit the
synthesis of an endogenous systemic media-
tor, such as platelet-activating factor. This
could have a bearing into the widespread sys-
temic effects of TOS.
In vitro studies. Several groups have
worked in the past on the study of the effects
elicited on various types of cell preparations
(mouse peritoneal macrophages, human tissue
polyps, human polymorphonuclear leuko-
cytes, and human endothelial cells), mostly by
fatty acid anilides and later by PAP esters.
Work with N-phenyllinoleamide has
shown that this anilide potentiates the
release of endogenous arachidonic acid from
cell membrane phospholipids and enhances
the metabolic pathways of the latter, increas-
ing the biosyntheses of its vasoactive endoge-
nous metabolites (59). However, Pich et al.
(60), using fatty acid anilides, described a
significantly reduced release of arachidonic
acid from cell membranes and impairment of
stimulated prostacyclin synthesis accompanied
by an antiﬁbrinolytic activity. This apparently
contrasting observation was explained by a
dual stimulatory and inhibitory effect on the
conversion of exogenous arachidonic acid as a
function of preincubation time with N-
phenyllinoleamide alone, because the oleic
acid anilide did not show any inhibitory effect
with incubation time.
N-phenyllinoleamide also undergoes
lipid oxidative metabolism, producing
hydroxylated and epoxylated compounds
structurally related to the metabolites arising
from linoleic acid but bearing the amide
moiety. This proves that N-phenylli-
noleamide can be metabolized via the same
hydroperoxidative processes acting upon
linoleic acid (61). These observations would
be in line with the peroxidative hypotheses
mediated by fatty acid anilides in TOS.
Work on polymorphonuclear leukocytes
showed that, as in rat liver, N-phenylli-
noleamide is metabolized to free aniline and
oxidative metabolites of linoleic acid (62).
Heiskanen et al. (63) have shown that the
anilides from palmitic, oleic, and linoleic
acids enhance reactive oxygen metabolites in
human polymorph nucleated leukocytes, but
this effect was also observed for the free oleic
and linoleic acids. The expression on leuko-
cyte adhesion molecules by linoleic acid, its
anilide, and arachidonic acid was not affected
in a whole blood assay (64). In addition,
these authors also worked with mono- and
dioleyl esters of PAP showing that, whereas
dioleyl esters of PAP slightly increased the
production of reactive oxygen metabolites in
polymorph nucleated leukocytes, PAP and its
oleyl mono ester had no effect (65).
Although extensive in their scope, most
of these studies do not provide a clear pic-
ture of the mechanism of TOS pathogenesis,
other than supporting in general the lipid
peroxidative hypothesis initially put forward
by various authors.
Discussion and Strategies for
Future Research
During the 1990s, substantial progress has
been made regarding both the identiﬁcation
of the causal agent and the interpretation 
of the biologic mechanisms of TOS.
Admittedly, 20 years after the outbreak, nei-
ther of these goals has been achieved, but in
the history of studies on the mechanisms of
environmentally induced disease, a delay of
decades is not surprising (a century and a
half elapsed between Percival Pott’s descrip-
tion of scrotal cancer in chimney sweepers
and Kennaway’s identification of carcino-
genic polycyclic hydrocarbons in soot).
• We have yet to determine the long-term
consequences of the TOS. It is reassuring
that no late excess of mortality in the
cohort has been detected. Up to the early
1990s (but not later), TOS victims died as
a consequence of the progression of the
disease, through a clinical continuum start-
ing in 1981.
• Fatty acid esters of PAP have been found
to a higher extent in oils consumed in
1981 by families in which TOS cases had
been recorded than in control oils. They
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Table 2. Summary of experiments carried out in animals using pure compounds contained in case oils.
Total no. of  Total no.  Median no.
Animal, strain Compounda experimentsb of animals of days Anilidesc OO PAPc
Mice
A/J LA 5 50 6 936.0 —
LL PAP 5 50 6 — 936.0
OA 5 50 6 936.0 —
OO PAP 5 50 6 — 936.0
B10.S LA 1 10 6 1875.0 —
LL PAP 1 10 14 — 2100.0
OA 2 22 24 13537.0 —
OO PAP 1 10 14 — 2100.0
MF1 O PAP 3 18 14 — 5250.0
PAP 3 18 14 — 3500.0
Swiss CFLP LA 6 157 5 2500.0 —
Subtotal 37 445
Rats
Lewis O PAP 3 18 14 — 5250.0
PAP 3 18 14 — 3500.0
Sprague-Dawley HLLA 1 45 7 1750.0 —
LLA 1 45 7 1750.0 —
LAC:P O PAP 3 18 14 — 5250.0
PAP 8 32 12 — 2800.0
Guinea pigs (Hartley)
LA 3 18 30 1500.0 —
OA 3 18 30 1500.0 —
OANT 3 18 30 1500.0 —
Subtotal 28 230
Total 65 675
aCompounds: LA, linoleyl anilide; LLA, linolenyl anilide; LL PAP, diester (dilinoleyl) of phenyl amine propanediol; HLLA,
heated linolenyl anilide; OANT, oleyl anilide synthetized by other groups (Purity not checked by the committee).
bExperiment = study carried out with a specific sample of oil using a strain following a specific schedule. cMedian of
dose (µg/kg body weight) intraperitoneal or intravenous, among all experiments carried out with this material in this
strain.have also been detected in oils synthesized
through industrial processes intended to
experimentally reproduce those imple-
mented at the time of the “accident.”
• PAP esters are an important group of
chemicals to which humans may be
exposed. Their toxicity has been investi-
gated to a limited extent, and current
efforts address their metabolism in labora-
tory animals and in vitro. Their postulated
ability to interfere with immunologic
changes is of interest.
• No etiologic theory alternative to the adul-
terated oil (such as an infection or a role
for organophosphorus compounds) is
based on scientiﬁc ﬁndings.
• Substantial evidence has been added to
the suggestion that TOS is the expression
of an immune disorder, most likely an
autoimmune condition. The autoim-
mune hypothesis is strengthened by a
number of observations: a postulated cas-
cade of events in TOS patients could be
T-cell activation, eosinophilia, release of
major basic proteins in tissues, and organ
impairment.
• Understanding the biologic mechanisms of
TOS has been hindered by the unavailabil-
ity of an animal model—that is, the “nat-
ural” occurrence of a similar condition in
animals. However, other conditions (such
as allergy) also lack a proper animal model.
Research on TOS has also been hindered
by the failure of all attempts to reproduce
TOS in experimental animals either with
oils believed to be case related or with oils
synthesized in the laboratory and contain-
ing high concentrations of aniline deriva-
tives. A possibility currently being pursued
is the use of SCID mice to which human
peripheral blood mononuclear cells have
been administered. 
• Knowledge of the metabolism of chemicals
implicated in TOS is diverse, and its signif-
icance is difﬁcult to evaluate.
Despite progress, many points still need
to be clariﬁed whose relevance surpasses that
of TOS itself. The implication of an
unknown toxic agent and the similarities of
the disease with other autoimmune patholo-
gies make TOS research an outstanding
scientific challenge. Priority areas for
investigation include immunologic and
metabolic factors and the study of the distri-
bution and toxicokinetics of candidate toxi-
cants in animal models. At the same time,
developing an animal model should be one
of the most important efforts, considering
the difficulty in reproducing an autoim-
mune disease in animals. Finally, another
basic objective in the clinical research on
TOS is the mortality follow-up and the
appearance of new outcomes in those who
remain alive.
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